Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.

Kidney transplantation is the treatment of choice for patients with end-stage renal disease. However, highly sensitized patients have a very difficult access to transplantation because of a very low number of compatible donors. Imlifidase is a major breakthrough in kidney transplantation, because it allows transplanting these highly sensitized patients considered as untransplantable until now. The findings coming from the ISKIA study will help to refine the use and implementation of imlifidase in this population. The main objective of this retrospective study is to analyze the efficacy and safety of kidney transplantations performed with a positive crossmatch against a deceased donor, where imlifidase is used in accordance to the French guidelines. The secondary objectives of the ISKIA study are: * To identify the characteristics and analyze the outcome of kidney recipients eligible to imlifidase but transplanted without imlifidase * To identify the characteristics of kidney recipients eligible to imlifidase but not transplanted